Abstract
Ionizing radiation exposure is associated with activation of certain immediate-early genes that function as transcription factors. These include members of jun or fos and early growth response (EGR) gene families. In particular, the functional role of EGR-1 in radiation-induced signaling is pivotal since the promoter of EGR-1 contains radiation inducible CArG DNA sequences. The Egr-1 gene belongs to a family of Egr genes that includes EGR-1, EGR-2, EGR-3, EGR-4, EGR-α and the tumor suppressor, Wilms tumor gene product, WT1. The Egr-1 gene product, EGR-1, is a nuclear protein that contains three zinc fingers of the C2H2 subtype. The EGR-1 GC-rich consensus target sequence, 5-GCGT / GGGGCG-3 or 5-TCCT / ACCTCCTCC-3, has been identifiedin the promoter regions of transcription factors, growth factors, receptors, cell cycle regulators and proapoptotic genes. The gene targets mediated by Egr-1 in response to ionizing radiation include TNF-α, p53, Rb and Bax, all these are effectors of apoptosis. Based on these targets, Egr-1 is a pivotal gene that initiates early signal transduction events in response to ionizing radiation leading to either growth arrest or cell death in tumor cells. There are two potential application of Egr-1 gene in therapy of cancer. First, the Egr-1 promoter contains information for appropriate spatial and temporal expression in-vivo that can be regulated by ionizing radiation to control transcription of genes that have pro-apoptotic and suicidal function. Secondly, EGR-1 protein can eliminate ‘induced-radiation resistance’ by inhibiting the functions of radiation-induced prosurvival genes (NFκB activity and bcl-2 expression) and activate proapoptotic genes (such as bax) to confer a significant radio-sensitizing effect. Together, the review of reported findings demonstrate clearly that EGR-1 is an early central gene that confers radiation sensitivity and its pro-apoptotic functions are synergized by abrogation of induced radiation resistance.
Keywords: egr-1, apoptosis, tnf-, bax, ionizing radiation
Current Cancer Drug Targets
Title: Regulation of Radiation-Induced Apoptosis by Early Growth Response-1 Gene in Solid Tumors
Volume: 4 Issue: 1
Author(s): Mansoor M. Ahmed
Affiliation:
Keywords: egr-1, apoptosis, tnf-, bax, ionizing radiation
Abstract: Ionizing radiation exposure is associated with activation of certain immediate-early genes that function as transcription factors. These include members of jun or fos and early growth response (EGR) gene families. In particular, the functional role of EGR-1 in radiation-induced signaling is pivotal since the promoter of EGR-1 contains radiation inducible CArG DNA sequences. The Egr-1 gene belongs to a family of Egr genes that includes EGR-1, EGR-2, EGR-3, EGR-4, EGR-α and the tumor suppressor, Wilms tumor gene product, WT1. The Egr-1 gene product, EGR-1, is a nuclear protein that contains three zinc fingers of the C2H2 subtype. The EGR-1 GC-rich consensus target sequence, 5-GCGT / GGGGCG-3 or 5-TCCT / ACCTCCTCC-3, has been identifiedin the promoter regions of transcription factors, growth factors, receptors, cell cycle regulators and proapoptotic genes. The gene targets mediated by Egr-1 in response to ionizing radiation include TNF-α, p53, Rb and Bax, all these are effectors of apoptosis. Based on these targets, Egr-1 is a pivotal gene that initiates early signal transduction events in response to ionizing radiation leading to either growth arrest or cell death in tumor cells. There are two potential application of Egr-1 gene in therapy of cancer. First, the Egr-1 promoter contains information for appropriate spatial and temporal expression in-vivo that can be regulated by ionizing radiation to control transcription of genes that have pro-apoptotic and suicidal function. Secondly, EGR-1 protein can eliminate ‘induced-radiation resistance’ by inhibiting the functions of radiation-induced prosurvival genes (NFκB activity and bcl-2 expression) and activate proapoptotic genes (such as bax) to confer a significant radio-sensitizing effect. Together, the review of reported findings demonstrate clearly that EGR-1 is an early central gene that confers radiation sensitivity and its pro-apoptotic functions are synergized by abrogation of induced radiation resistance.
Export Options
About this article
Cite this article as:
Ahmed M. Mansoor, Regulation of Radiation-Induced Apoptosis by Early Growth Response-1 Gene in Solid Tumors, Current Cancer Drug Targets 2004; 4 (1) . https://dx.doi.org/10.2174/1568009043481704
DOI https://dx.doi.org/10.2174/1568009043481704 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Xanthones as Potential Antioxidants
Current Medicinal Chemistry Lectin Techniques for Glycoproteomics
Current Proteomics Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Quantitative Proteomics for Cancer Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Aceruloplasminemia
Current Drug Targets <sup>68</sup>Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with <sup>68</sup>Ga-NODAGA-AE105
Anti-Cancer Agents in Medicinal Chemistry Lycorine and its Derivatives for Anticancer Drug Design
Mini-Reviews in Medicinal Chemistry Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Novel Approaches to Cancer Therapy Using Oncolytic Viruses
Current Molecular Medicine Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery High Order Texture-Based Analysis in Biomedical Images
Current Medical Imaging A Comparative Study of Two Novel Nanosized Radiolabeled Analogues of Methionine for SPECT Tumor Imaging
Current Medicinal Chemistry Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer
Current Cancer Drug Targets Anti-Carcinogenic Effects of Carnosol-An Updated Review
Current Drug Discovery Technologies